Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Bloodbuy, Teaching Plan
Hamermesh, Richard G.; Quelch, John A.; Norris, MichaelNota del Instructor HBS-815140-EIniciativa emprendedoraTeaching plan for case 815114.Desde 0,00 €
-
Weibo: The Chinese Social Media Business Model - Teaching Note
Yibo Lyu; Shaojie Han; Qing Liu; Jingqin Su; Jianen SunNota del Instructor IVEY-8B19M081-EDirección estratégicaTeaching note for product 9B19M081.Desde 0,00 €
-
IDL: Enabling the Conventional Retail Industry - Teaching Note
Yibo Lyu; Lining Bao; Qing Liu; Yushan Zhou; Shaojie Han; Liangqi Xu; Jianen Sun; Chun Kong AuNota del Instructor IVEY-8B20A042-EMarketingTeaching note for product 9B20A042.Desde 0,00 €
-
MedImmune Ventures, Teaching Plan
Hamermesh, Richard G.; Otazo, AndrewNota del Instructor HBS-814039-EIniciativa emprendedora"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets.Desde 0,00 €
-
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
Hamermesh, Richard G.; Kucherlapati, Raju; Gordon, RachelCaso HBS-810066-EIniciativa emprendedoraIn May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had received approval several years prior. Moreover, Vectibix had also received Food and Drug Administration approval in 2006. During additional trials, Amgen has learned that the Vectibix...Desde 8,20 €